Samsung Biologics saw the highest growth of 49% in patent filings and 99% in grants in December in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 49% and grants by 99%. GlobalData’s DataBook provides a comprehensive analysis of Samsung Biologics‘s patent filings and grants. Buy the databook here.
Samsung Biologics has been focused on protecting inventions in European Patent Office(EPO) with one publication in Q4 2023
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 100% filings and 0% grants. The European Patent Office(EPO), and Israel(IL) patent Office are among the top ten patent offices where Samsung Biologics is filings its patents. Among the top granted patent authorities, Samsung Biologics has 100% of its grants in Israel(IL)
Johnson & Johnson and F. Hoffmann-La Roche could be the strongest competitors for Samsung Biologics
For comprehensive analysis of Samsung Biologics's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.